Aligos Therapeutics' Shares Rally Following $25M Payment from Xiamen Amoytop Biotech

Dow Jones

07/07

Shares of Aligos Therapeutics surged after the company received a $25 million upfront payment as part of a licensing deal with Xiamen Amoytop Biotech.

The stock was up 20% to $7.02 in after-hours trading Monday. Shares closed the market session up 4.7% at $5.85, but are still down 37% this year.

The pact between the two companies is for pevifoscorvir sodium, a hepatitis B treatment, in Greater China.

Aligos said it was eligible to receive up to $420 million in payments based on clinical, regulatory and sales milestones. The clinical stage biopharmaceutical company also said it may receive tiered, high-single-digit royalties on net sales in Amoytop's licensed territories.

Aligos retains all development and commercialization rights for pevifoscorvir sodium in all other markets, including the U.S., Europe and South Korea.

Chief Executive Lawrence Blatt said Amoytop would introduce Aligos' antisense oligonucleotide into the clinic in China in the third quarter.

Write to Grace Yoon at grace.yoon@wsj.com

(END) Dow Jones Newswires

July 06, 2026 17:53 ET (21:53 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2649674118"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2649674118\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2649674118?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-07 05:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649674118","market":"other","top_or_hot":-1,"title":"Aligos Therapeutics' Shares Rally Following $25M Payment from Xiamen Amoytop Biotech","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Aligos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> surged after the company received a $25 million upfront payment as part of a licensing deal with <a href=\"https://laohu8.com/S/688278\">Xiamen Amoytop Biotech</a>. \n</p>\n<p>\n  The stock was up 20% to $7.02 in after-hours trading Monday. Shares closed the market session up 4.7% at $5.85, but are still down 37% this year. \n</p>\n<p>\n  The pact between the two companies is for pevifoscorvir sodium, a hepatitis B treatment, in Greater China. \n</p>\n<p>\n  Aligos said it was eligible to receive up to $420 million in payments based on clinical, regulatory and sales milestones. The clinical stage biopharmaceutical company also said it may receive tiered, high-single-digit royalties on net sales in Amoytop's licensed territories. \n</p>\n<p>\n  Aligos retains all development and commercialization rights for pevifoscorvir sodium in all other markets, including the U.S., Europe and South Korea. \n</p>\n<p>\n  Chief Executive Lawrence Blatt said Amoytop would introduce Aligos' antisense oligonucleotide into the clinic in China in the third quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 06, 2026 17:53 ET (21:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aligos Therapeutics' Shares Rally Following $25M Payment from Xiamen Amoytop Biotech</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAligos Therapeutics' Shares Rally Following $25M Payment from Xiamen Amoytop Biotech\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-07-07 05:53</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Aligos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> surged after the company received a $25 million upfront payment as part of a licensing deal with <a href=\"https://laohu8.com/S/688278\">Xiamen Amoytop Biotech</a>. \n</p>\n<p>\n  The stock was up 20% to $7.02 in after-hours trading Monday. Shares closed the market session up 4.7% at $5.85, but are still down 37% this year. \n</p>\n<p>\n  The pact between the two companies is for pevifoscorvir sodium, a hepatitis B treatment, in Greater China. \n</p>\n<p>\n  Aligos said it was eligible to receive up to $420 million in payments based on clinical, regulatory and sales milestones. The clinical stage biopharmaceutical company also said it may receive tiered, high-single-digit royalties on net sales in Amoytop's licensed territories. \n</p>\n<p>\n  Aligos retains all development and commercialization rights for pevifoscorvir sodium in all other markets, including the U.S., Europe and South Korea. \n</p>\n<p>\n  Chief Executive Lawrence Blatt said Amoytop would introduce Aligos' antisense oligonucleotide into the clinic in China in the third quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 06, 2026 17:53 ET (21:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688278","symbol_name":"特寶生物","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2649674118","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649674118","pubTimestamp":1783374780,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Aligos Therapeutics surged after the company received a $25 million upfront payment as part of a licensing deal with Xiamen Amoytop Biotech.The stock was up 20% to $7.02 in after-hours trading Monday. Shares closed the market session up 4.7% at $5.85, but are still down 37% this year.The pact between the two companies is for pevifoscorvir sodium, a hepatitis B treatment, in Greater China.Aligos said it was eligible to receive up to $420 million in payments based on clinical, regulatory and sales milestones. The clinical stage biopharmaceutical company also said it may receive tiered, high-single-digit royalties on net sales in Amoytop's licensed territories.Aligos retains all development and commercialization rights for pevifoscorvir sodium in all other markets, including the U.S., Europe and South Korea.Chief Executive Lawrence Blatt said Amoytop would introduce Aligos' antisense oligonucleotide into the clinic in China in the third quarter.Write to Grace Yoon at grace.yoon@","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688278":"特宝生物","BK4585":"ETF&股票定投概念","BK4581":"高盛持仓","BK0239":"医药制造","BK4588":"碎股","XBI":"SPDR S&P Biotech ETF","BK4505":"高瓴资本持仓","BK4139":"生物科技","ALGS":"Aligos Therapeutics, Inc."},"translate_title":"厦门淘拓生物科技支付2500万美元后，Aligos Therapeutics股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688278":0.9,"ALGS":1.5,"XBI":1.5},"content_text":"Shares of Aligos Therapeutics surged after the company received a $25 million upfront payment as part of a licensing deal with Xiamen Amoytop Biotech. \n\n\n  The stock was up 20% to $7.02 in after-hours trading Monday. Shares closed the market session up 4.7% at $5.85, but are still down 37% this year. \n\n\n  The pact between the two companies is for pevifoscorvir sodium, a hepatitis B treatment, in Greater China. \n\n\n  Aligos said it was eligible to receive up to $420 million in payments based on clinical, regulatory and sales milestones. The clinical stage biopharmaceutical company also said it may receive tiered, high-single-digit royalties on net sales in Amoytop's licensed territories. \n\n\n  Aligos retains all development and commercialization rights for pevifoscorvir sodium in all other markets, including the U.S., Europe and South Korea. \n\n\n  Chief Executive Lawrence Blatt said Amoytop would introduce Aligos' antisense oligonucleotide into the clinic in China in the third quarter. \n\n\n \n\n\n  Write to Grace Yoon at grace.yoon@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 06, 2026 17:53 ET (21:53 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}